Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

NCT01331824 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
22
Enrollment
OTHER
Sponsor class

Stopped due to a development decision by the funder

Conditions

Interventions

Sponsor

Matthew Galsky

Collaborators